Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase NA 7Phase 1/2 5Phase 3 3Phase 2/3 3Phase 1 1

Status

Unknown 4Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Neoplasms 2Esophageal Squamous Cell Carcinoma 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Hepatic Metastasis of Colorectal Cancer 1Esophageal Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colorectal Cancer Recurrent 1Carcinoma, Non-Small-Cell Lung 1CRC 1

Interventions

Sorafenib 26Nivolumab 21pembrolizumab 15Bevacizumab 14lenvatinib 12atezolizumab 9Cyclophosphamide 9Ipilimumab 8durvalumab 6camrelizumab 5apatinib 5Specimen Handling 5Radiosurgery 5tislelizumab 4fludarabine 4Immunotherapy, Adoptive 4Fluorouracil 4Doxorubicin 4tremelimumab 3toripalimab 3sintilimab 3regorafenib 3cabozantinib 3X-Rays 3Magnetic Resonance Spectroscopy 3Injections 3Everolimus 3Ethiodized Oil 3Erlotinib Hydrochloride 3tepotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Hepatocellular × camrelizumab × Clear all
NCT05924997 2024-02-21

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2 Unknown
52 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06124001 2023-11-15

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

CNBG-Virogin Biotech (Shanghai) Ltd.

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04443309 2023-03-29

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

Peking Union Medical College Hospital

Phase 1/2 Unknown
53 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04035876 2019-07-29

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Zhejiang University

Phase 1/2 Unknown
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02942329 2018-02-26

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Phase 1/2 Unknown
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡